PDF(Pubmed)
Abstract：
Although patients with hyperuricemia and gout often have dyslipidemia, the effects of febuxostat, a xanthine oxidase inhibitor, on their lipid profiles are unclear. Thus, we performed a sub-analysis of the randomized PRIZE study in which the effects of febuxostat on carotid atherosclerosis were investigated in patients with hyperuricemia. The participants were randomized to the febuxostat or control group. The primary endpoint of this sub-analysis was changes in the patients\' non-high-density lipoprotein cholesterol (HDL-C) levels from baseline to 6-month follow-up. Correlations between the changes in lipid profiles and cardiometabolic parameters were also evaluated. In total, 456 patients were included. From baseline to 6 months, non-HDL-C levels were significantly reduced in the febuxostat group (-5.9 mg/dL, 95% confidence interval [CI]: -9.1 to -2.8 mg/dL, p < 0.001), but not in the control group (-1.3 mg/dL, 95% CI: -4.4 to 1.8, p = 0.348). The reduction in non-HDL-C levels was more pronounced in women and correlated with changes in serum uric acid and estimated glomerular filtration rate levels only in the febuxostat group. In patients with hyperuricemia, febuxostat treatment was associated with reduced non-HDL-C levels from baseline to the 6-month follow-up compared to the control treatment, suggesting that the lipid-lowering effect of febuxostat should be considered when targeting dyslipidemia.
摘要：
尽管高尿酸血症和痛风患者经常有血脂异常，非布索坦的作用,黄嘌呤氧化酶抑制剂,他们的血脂谱不清楚。因此，我们对随机PRIZE研究进行了亚分析,该研究在高尿酸血症患者中研究了非布索坦对颈动脉粥样硬化的影响.参与者被随机分配到非布索坦或对照组。该子分析的主要终点是患者非高密度脂蛋白胆固醇（HDL-C）水平从基线到6个月随访的变化。还评估了脂质分布变化与心脏代谢参数之间的相关性。总的来说,456名患者被包括在内。从基线到6个月，非布索坦组非HDL-C水平显着降低（-5.9mg/dL，95%置信区间[CI]：-9.1至-2.8mg/dL，p<0.001)，但对照组并非如此（-1.3mg/dL，95%CI：-4.4至1.8，p=0.348）。非HDL-C水平的降低在女性中更为明显，并且仅在非布索坦组中与血清尿酸的变化和估计的肾小球滤过率水平相关。在高尿酸血症患者中，与对照治疗相比，非布索坦治疗与从基线到6个月随访的非HDL-C水平降低相关，提示针对血脂异常时，应考虑非布索坦的降脂作用。
